Champions Oncology, INC Form 4 insider transactions

Champions Oncology, Inc. CEO Robert Lawrence Brainin received 700,000 stock options with various performance and time-based vesting conditions.

Robert L. Brainin, a Director at Champions Oncology, Inc., was granted a series of stock options with varying exercise prices and vesting schedules.

Champions Oncology Director Philip P. Breitfeld acquired 13,790 options to purchase common stock at an exercise price of $6.80, vesting over 12 months.

Champions Oncology Director David Sidransky was granted 21,216 stock options with an exercise price of $6.8, vesting over 12 months starting November 5, 2025.

Champions Oncology Director Daniel Mendelson was granted options to purchase 13,790 shares of common stock at an exercise price of $6.80 per share.

Champions Oncology Director and 10% owner Scott R. Tobin acquired 25,460 stock options with an exercise price of $6.80, vesting over 12 months.

Champions Oncology Director Joel Ackerman acquired 21,216 options to purchase common stock at an exercise price of $6.80 per share.

Champions Oncology Director Joel Ackerman exercised options to acquire 94,405 shares of common stock at $2.10 per share.

Director Philip P. Breitfeld reported the disposal of 4,150 shares of Champions Oncology, Inc. common stock via a transfer to a donor-advised charitable trust fund.

Philip P. Breitfeld, a director at Champions Oncology, Inc., has acquired options to purchase 18,715 shares of common stock.

David Sidransky, a director at Champions Oncology, acquired 21,880 stock options on November 12, 2024.

Daniel Mendelson, a director at Champions Oncology, acquired 21,590 stock options on November 12, 2024.

Scott R. Tobin, a director at Champions Oncology, Inc., has acquired 34,550 stock options.

Joel Ackerman, a director at Champions Oncology, acquired options to purchase 43,190 shares of common stock.

Joel Ackerman, a director at Champions Oncology, Inc., reports exercising options to purchase common stock at prices of $2.1 and $5.43, resulting in adjustments to his beneficial ownership.

Brady Davis, President of Champions Oncology, Inc., reports the acquisition of options to purchase common stock in a recent SEC Form 4 filing.